CCR2 and neoplasm: When the monocyte-depleting anti-CCR2 antibody MC-21 was injected after DIVA2, a temporary reduction in tumor growth was observed, suggesting that the immunosuppressive phenotype of the CCR2+ tumor-infiltrating monocytes is responsible for the failure of tumor specific T cells to eradicate tumors.